Lipicard Technologies

Lipicard Technologies is a specialty pharmaceutical company that focused on the development of novel formulations for cardiovascular and metabolic diseases. Founded by Dr. Michael Davidson, a prominent lipidologist, the company is best known for developing Lipofen, a proprietary formulation of fenofibrate. Lipofen was designed to improve the bioavailability of the drug, allowing it to be administered without the strict dietary requirements associated with earlier fenofibrate products. The company successfully licensed the global rights for Lipofen to Cipher Pharmaceuticals, leading to its FDA approval in 2006. Lipicard's strategy involved enhancing the therapeutic value of existing compounds through innovative drug delivery and formulation technologies.